Carboranes increase the potency of small molecule inhibitors of nicotinamide phosphoribosyltranferase

Journal of Medicinal Chemistry

Volumn 55, Issue 16, 2012, Pages 7290-7294

  Lee, Mark W ^a   Sevryugina, Yulia V ^a   Khan, Aslam ^a   Ye, Shui Q ^b  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBORANE DERIVATIVE; ENZYME INHIBITOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SMALL MOLECULE INHIBITOR OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; STRUCTURE ANALYSIS;

EID: 84866914836     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300740t     Document Type: Article

References (22)

1. Issa, F.; Kassiou, M.; Rendina, L. M. Boron in drug discovery: carboranes as unique pharmacophores in biologically active compounds. Chem. Rev. 2011, 111, 5701-5722.
2. Grimes, R. N. Carboranes, 2nd ed; Academic Press: Burlington, MA, 2011.
3. Valliant, J. F.; Guenther, K.; King, A.; Morel, P.; Schaffer, P.; Sogbein, O.; Stephenson, K. The medicinal chemistry of carboranes. Coord. Chem. Rev. 2002, 232, 173-230.
4. Barth, R. F.; Coderre, J.; Vicente, M. G.; Blue, T. E. Boron neutron capture therapy of cancer: current status and future prospects. Clin. Cancer Res. 2005, 32, 950-984.
5. Endo, Y.; Iijima, T.; Yamakoshi, Y.; Fukasawa, H.; Miyaura, C.; Inada, M.; Kubo, A.; Itai, A. Potent estrogenagonists based on carborane as a hydrophobic skeletal structure a new medicinal application of boron clusters. Chem. Biol. 2001, 11, 3987-4002.
6. Cígler, P.; Kozísek, M.; Rezacova, P.; Brynda, J.; Otwinowski, Z.; Pokorna, J.; Plesek, J.; Gruner, B.; Doleckova-Maresova, L.; Masa, M.; Sedlacek, J.; Bodem, J.; Krausslich, H.; Kral, V.; Konvalinka, J. From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 15394-15399.
7. Beer, M.; Lemon, J.; Valliant, J. Preparation and evaluation of carborane analoues of tamoxifen. J. Med. Chem. 2010, 53, 8012-8020.
8. Scholz, M.; Kaluderovic, G.; Kommera, H.; Paschke, R.; Will, J.; Sheldrick, W.; Hey-Hawkins, E. Carbaboranes as pharmacophores: similarities and differences between aspirin and asborin. Eur. J. Med. Chem. 2011, 46, 1131-1139.
9. Fanfrlík, J.; Lepsík, M.; Horinek, D.; Havlas, Z.; Ho, P. Interaction of carboranes with biomolecules: formation of dihydrogen bonds. Chem. Phys. Chem. 2006, 7, 1100-1105.
10. Crabtree, R. H.; Siegbahn, P.; Eisenstein, O.; Rheingold, A.; Koetzle, T. A new intermolecular interaction: unconventional hydrogen bonds with element-hydride bonds as proton. Acc. Chem. Res. 1996, 29, 348-354.
11. Tong, J.; Forouhar, F.; Tao, X.; Tong, L. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin. Ther. Targets 2007, 11, 695-705.
12. Galli, M.; Van Gool, F.; Rongvaux, A.; Andris, F.; Leo, O. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res. 2009, 70, 8-11.
13. Garten, A.; Petzold, S.; Korner, A.; Imai, S.; Kiess, W. Nampt: linking NAD biology, metabolism, and cancer. Trends Endocrinol. Metab. 2009, 20, 130-138.
14. Revollo, J.; Grimm, A.; Imai, S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 2004, 279, 50754-50763.
15. + levels dictate cell survival. Cell 2007, 130, 1095-1107.
16. Hasmann, M.; Schemainda, I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003, 63, 7436-7442.
17. Khan, J.; Tao, X.; Tong, L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat. Struct. Mol. Biol. 2006, 13, 582-588.
18. Tiwari, R.; Mahasenan, K.; Pavlovicz, R.; Li, C.; Tjarks, W. Carborane clusters in computational drug design: a comparative docking evaluation using AutoDock, Flexx, Glide and Surflex. J. Chem. Inf. Model. 2009, 49, 1581-1589.
19. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methids 1983, 65, 55-63.
20. Grimes, R. N. Boron clusters come of age. J. Chem. Educ. 2004, 81, 657-672.
21. Laubengayer, A.; Kysz, W. The dipole moments of the isomers of dicarbadecaborane. Inorg. Chem. 1965, 4, 1513-1514.
22. Busso, N.; Karababa, M.; Nobile, M.; Rolaz, A.; Van Gool, F.; Galli, M.; Leo, O.; So, A.; De Smedt, T. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 2008, 21, e2267.